clinical trial · NCT07072195
A Study of AMC6156 in People With Sarcopenia
Sarcopenia in ElderlySarcopeniaAMC6156 0.1mgAMC6156 0.3mgAMC6156 1.0mgPlacebo
brief summary
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
started
Jul 1, 2025
primary completion
Mar 1, 2026
completion
Jun 1, 2026
last updated
Jul 29, 2025
official title
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol